Hello, Guest!
  • Friday, November 22, 2024

SRI International Books $100M NIH Contract for Medical Countermeasure R&D Services

An SRI International division has secured a potential seven-year, $100M contract to help a National Institutes of Health component develop methods to medical conditions caused by direct exposure or contamination from radioactive materials.

SRI Biosciences will support the National Institute of Allergy and Infectious Diseases in research and development of medical countermeasures for radiological and nuclear emergencies, the nonprofit said Wednesday.

The partnership will also explore biological dosimetry tests and advance candidate treatments for acute radiation syndromes, delayed effects from acute radiation exposure and internal radionuclide contamination.

Both NIH and NIAID have worked with SRI Biosciences to develop radiation therapies as part of a contract slated to expire this month.

Video of the Day

Related Articles

HHS’ $5B Project NextGen Kicks Off Activities to Streamline Vaccine Development, Commercialization Healthcare IT

HHS’ $5B Project NextGen Kicks Off Activities to Streamline Vaccine Development, Commercialization

The Department of Health and Human Services has outlined several focus areas of a $5 billion government initiative to fund public-private collaborations working to speed up the development of next-generation vaccines and other therapeutics. Project NextGen aims to streamline the process from drug development to government approval to prepare and protect the country from future

HHS, DOD Sign $3.65B in COVID-19 Vaccine Deals With Pfizer-BioNTech, Moderna News

HHS, DOD Sign $3.65B in COVID-19 Vaccine Deals With Pfizer-BioNTech, Moderna

The departments of Health and Human Services and Defense have earmarked $3.65 billion to buy 100 million additional doses of COVID-19 vaccines each from Pfizer (NYSE: PFE) and Moderna (Nasdaq: MRNA), bringing the total number of vaccines bought from the companies to 600 million doses. The U.S. government agreed to pay $2 billion to Pfizer and its Germany-based partner BioNTech and $1.65 billion to Moderna for the additional doses.

HHS, DoD Ink $1.5B Deal With Moderna for COVID-19 Vaccine Production Contract Awards

HHS, DoD Ink $1.5B Deal With Moderna for COVID-19 Vaccine Production

The departments of Health and Human Services and Defense have signed a potential $1.5B agreement with Moderna to produce 100M doses of its COVID-19 vaccine candidate as part of the U.S. government’s Operation Warp Speed.